Post Profile

Clinical trial investigates new treatment for systolic heart failure patients

(University of Alberta Faculty of Medicine & Dentistry) The academic partners in the VerICiguaT GlObal Study in Subjects with Heart Failure with Reduced EjectIon FrAction (VICTORIA) are pleased to announce that patient enrollment has begun. The study will explore a novel treatment pathway in patients suffering from chronic heart failure with reduced ejection fraction (HFrEF), by investigating the clinical impact of the drug vericiguat.
read more


Related Posts

Harvest Technologies Announces Initial Enrollment In Its REVIVE-1 Trial (REtrograde Vascular Infusion Of BMAC To ImproVe Heart FailurE)

Health : Medical News Today

Harvest Technologies Corp. announced that the first twelve patients of its sixty patient Heart Failure trial have been enrolled at Medanta-the Medicity in Gurgaon INDIA. The trial is intended to evaluate the safety and clinical effe...

Discovery and gene therapy treatment of a novel heart failure mechanism

Health : EurekAlert: Health

(Kumamoto University) A key protein that causes heart failure has been revealed through new research from a collaboration based in Kumamoto University, Japan. The protein is secreted by cardiac muscle cells and reduces heart functio...

Researchers find comparable long-term outcomes between diastolic and systolic heart failure patients

Academics / General Science : Science Codex

(Boston) – A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction comm...

Saint Louis University Enrolls First U.S. Patient in Rare Heart Disease Trial

Health : Newswise Medical News

Earlier this year, investigators at Saint Louis University enrolled the first U.S. patient in a worldwide Phase 3 clinical trial of a medication to treat patients who have a rare form of heart failure due to a gene mutation.

Heart Failure Patients With Preserved Ejection Fraction May Benefit From New Drug, LCZ696

Health : Medical News Today

LCZ696, a first-in-class compound, may improve treatment outcomes for half of all patients with heart failure, according to a Phase II clinical trial on heart failure patients with preserved ejection fraction; preserved ejection fra...


Copyright © 2016 Regator, LLC